Neurológia pre prax 4/2020

Longterm safety of Ocrelizumab in Multiple Sclerosis treatment

A huge shift has been made in the field of Multiple Sclerosis treatment in the last decades. New modern medicaments have brought us the ability to suppress the disease activity and thereby save the patients from becoming invalid in the future. Therefore, the main feature of these drugs must be not only their efficiency, but also long-term safety. And so, we collect long-term data about the efficiency and safety of these new medicaments. This article focuses on the data of ocrelizumab. A remedy that is used today to treat not only relapse remittent form of MS but also is the first remedy in history used to treat primary progressive form of MS.

Keywords: multiple sclerosis, long-term safety, ocrelizumab, infusion related reactions, infections, malignancies